Deborah’s innovative Clinical Research Department is currently involved in over 30 innovative trials exploring new treatments and procedures in Electrophysiology, Interventional Cardiology, Peripheral Vascular Disease, and Preventive Cardiology. In addition to highly committed and talented Principal Investigators, the Clinical Research Team at Deborah provides superior patient support through its research associates, who keep both referring physicians and patients apprised of not only their progress, but that of the clinical research study, at each step of the way.
Pedram Kazemian, MD, MSc, FRCPC, FACP, Medical Director, Clinical Research
The Radiance HTN Study
If you have Hypertension, you are not alone. Learn about a clinical study for the potential treatment of high blood pressure.
LUCY Study Focuses on Endovascular Treatment of Abdominal Aortic Aneurysms (AAAs) in Women Compared to Men
The LUCY study, “TriVascular Evaluation of Females Who are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair,” examines the potential for improved clinical outcomes associated with using the Ovation® Abdominal Aortic Stent Graft platform for endovascular repair of abdominal aortic aneurysms (EVAR) in women as well as men. The lack of adequate treatment options — primarily due to more conventional large bore EVAR systems — is a persistent issue for female AAA patients. Clinical literature shows that women diagnosed with AAAs experience aortic expansion at a rate that is 40-80% faster than men, which can result in aortic rupture at smaller diameters. Due to their smaller stature, women with AAAs also typically have smaller femoral arteries, resulting in more challenges with vascular access. Often there may also be hostile aortic neck anatomy, resulting in significantly decreased options for on-label EVAR treatment.
Principal Investigator Richard Kovach, MD, Chair, Interventional Cardiology and Director, Cardiac Catheterization Laboratory.
For more information, please contact Luot Lewis, LUCY Study Coordinator at 609-893-1200 ext. 5022.
Developed by Veryan and based on biomimicry, the new BioMimics 3D® stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology is designed to enhance clinical performance by improving flow conditions and biomechanical performance of stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide more flexibility — as well as kink and fracture resistance, in comparison to other laser-cut nitinol tube stents — making its unique design of particular importance in the hostile environment of the femoropopliteal artery.
The BioMimics 3D stent has a unique helical curvature to impart natural geometry to the diseased artery, promoting secondary (swirling) flow and elevated hemodynamic shear stress, which has a protective effect on the endothelium. The helical geometry of the BioMimics 3D femoropopliteal stent is also designed to enable coil-spring shortening of the stented segment during knee flexion and thus mitigate the risk of stented segment compression causing localized strains, which in a straight stent may lead to stent fracture and chronic vascular injury.
Principal Investigator: Vincent Varghese, DO, Attending, Interventional Cardiology and Endovascular Medicine; Research Coordinator: Alyssa Bates 609-893-1200 ext. 5019
Parachute® Ventricular Partitioning Device
This technology offers hope to those suffering from heart failure caused by damage to and weakening of the heart muscle following a heart attack.
Through a catheter inserted in the femoral artery, the Parachute implant is deployed in the left ventricle to partition the damaged muscle, excluding the non-functional heart segment from the healthy, functional segment to decrease the overall volume of the left ventricle and restore its geometry efficiently and functionality.
Principal Investigator: Richard Kovach, MD, Chair, Interventional Cardiology and Jennifer Mazzoni, DO, FACC, Cardiology
For information on ongoing Clinical Trials or to refer your patient please contact Linda Dewey, RN, MSN, CCRC, Senior Study Coordinator, Department of Clinical Research at 609-893-1200 ext. 5023, Fax: 609-735-1472, Attention Linda. E-mail: DeweyL@deborah.org
Published in Cath Lab Digest
Percutaneous Intervention of a Complex Ventricular Septal Defect Author(s): Harit Desai, DO; Nemalan Selvaraj, DO; Ulrich Luft, MD and Jon C. George, MD; Division of Interventional Cardiology and Endovascular Medicine, Deborah Heart and Lung Center, Browns Mills, New Jersey
Published Research Deborah Has Participated In:
- Patterns of Anticoagulation Following Bioprosthetic Valve Implantation: Observations from ANSWER